While further in‐depth analysis from the BETonMACE trial is still ongoing, BET inhibition in T2DM patients seems to show therapeutic impact on CV events and highlights the potential for specifically targeting other BET proteins, such as BRD4, that may prove to be an effective therapeutic strategy for patients with DCM. Here, BRD4 is linked to familial dilated cardiomyopathy.